Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Cellectar Biosciences Expands Global Intellectual Property Estate
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Perrigo (NYSE:PRGO) & Cellectar Biosciences (NASDAQ:CLRB) Critical Survey
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
4 Medical Product Stocks to Watch From a Challenging Industry
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Cellectar Announces Plan to Explore Strategic Alternatives
4 Medical Product Stocks to Buy From a Challenging Industry
Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?
Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
Wall Street's top 5 stocks with the biggest upside in 2025